+
Site Tour

Search

Showing 111 - 120 of 459 results.

  • Prevention

    AF AND THE CHALLENGES OF MEDICATION Many patients at risk of stroke want an alternative to oral anticoagulants (OACs), for example, warfarin and non-vitamin K oral anticoagulants (NOACs).7 40% Do N
  • Diagnosis

    Characteristics that are strongly associated with a causal role of PFO in an ischemic stroke of unknown cause are:9 Atrial septal aneurysm (ASA) and/or a moderate-to-severe shunt Atrial septal
  • Guidelines & Recommendations

    Compelling data resulted in positive guidelines recommending PFO closure Long-term data from the both the RESPECT trial12 and REDUCE trial,13 as well as data from the CLOSE trial,14 have revealed tha
  • Guidelines

    Summary of current relevant international guidelines on the diagnosis of TR TR should be evaluated first by echocardiography. In primary TR, specific abnormalities of the valve can be identified.
  • 404 - Page not found

    404 Page not found The location may have changed Please double-check the web address, look for your topic via search or look at our sitemap.  
  • Sitemap

    SITEMAP
  • Treatment

    Patients may also receive a remote monitoring system which allows them to transmit data to the doctor without an in-office visit. CLASS II Slight limitation of physical activity. Comfortable at re
  • Diagnosis

    Figure 1: The diagnostic algorithm for heart failure. BNP=B-type natriuretic peptide; ECG=electrocardiogram; HFmrEF=heart failure with mildly reduced ejection fraction; HFpEF=heart failure with pres
  • Clinical Data

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding PFO closure THE LANDMARK RESPECT TRIAL2STILL THE DEFINITIVE CLINICAL TRIAL ON PFO
  • Guidelines & Recommendations

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding PFO closure Among patients aged 18–65 who have had a cryptogenic ischemic stroke,

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline